According to the latest published NCCN prostate cancer guidelines, CT, MRI, PET/CT, or PET/MRI with F-18 NaF C-11 choline, F-18 fluciclovine, Ga-68 PSMA-11, or F-18 piflufolastat PSMA can be considered for evaluating equivocal results on initial bone imaging [4]. The gene discussed is FOLH1; the disease is prostate carcinoma.